Skip to content

PERCEPIC: PERC Rule Combined With Implicit Low Clinical Probability

Performance of the Pulmonary Embolism Rule-out Criteria (the PERC Rule) Combined With Implicit Low Clinical Probability (Gestalt) to Rule-out PE Without Further Exams

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02360540
Acronym
PERCEPIC
Enrollment
1773
Registered
2015-02-10
Start date
2015-05-31
Completion date
2016-07-31
Last updated
2016-09-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dyspnea, Pulmonary Embolism, Thoracic Pain

Keywords

Pulmonary Embolism, Diagnostic strategy, Exclusion, Clinical probability, Implicit Judgment (Gestalt), PERC

Brief summary

PERC rule was created to rule out pulmonary embolism (PE) without further exams, with residual PE risk \<2%. Its safety is currently confirmed in low PE prevalence populations as north-American. In European high PE prevalence population, it has been showed that PERC rule used alone or associated with low clinical probability assessed by revised Geneva score (RGS) was not safe. In retrospective study, we suggest that the combination of PERC rule with implicit clinical probability (gestalt) could allow the use of the PERC rule. PERCEPIC, an observational prospective multicenter study performed in France and Belgium, will test this hypothesis. Therefore, 3000 patients will be included in 12 centers. Primary outcome will be the rate of thromboembolic events or death related or possibly related to PE in patients with low implicit clinical probability and negative PERC rule (8 criteria absents). Upper limit of confidence interval of this rate must be equal or lower than 3% to consider PERC rule as safe in this combination.

Interventions

OTHERGestalt estimation

Sponsors

Cliniques universitaires Saint-Luc- Université Catholique de Louvain
CollaboratorOTHER
University Hospital, Angers
Lead SponsorOTHER_GOV

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

\- Patients admitted to the emergency department for one of the following criteria : * Dyspnea and/or Thoracic pain without another obvious cause * Pulmonary embolism suspicion whatever the reason

Exclusion criteria

* Age lower than 18 * Patients hospitalized for more than 48h * Ongoing curative anticoagulant therapy for more than 48h before admission * Patients with thromboembolic disease diagnosed before the admission * Unavailability for follow-up (short life expectancy, no phone number…) * Patient refusing to be contacted by phone at 3 month * Patient refusing that medical data were collected * Secondary

Design outcomes

Primary

MeasureTime frameDescription
To assess the accuracy of the combination of low implicit clinical probability (gestalt) and negative PERC rule (8 criteria absents)3 monthsRate of thromboembolic events or death related or possibly related to PE in patients with low implicit clinical probability and negative PERC rule. Upper limit of confidence interval of this rate must be equal or lower than 3% to consider PERC rule as safe in this combination

Secondary

MeasureTime frameDescription
To assess usefulness of PERC and implicit low clinical probability combination to reduce the use of further examsDuring emergency managmentMean number of further exams performed per diagnostic strategy
To assess the accuracy of PERC and low clinical probability combination depending of clinical probability assessment method (implicit assessment, revised Geneva Score, Wells Score and implicit overridden Geneva Score)3 monthsFor each methods, AUC in receiver operating characteristic analyses of the 3-level classification scheme will be compared.
To compare performances of clinical probability assessment methods : implicit assessment, revised Geneva Score, Wells Score and implicit overridden Geneva Score3 monthsFor each methods, AUC in receiver operating characteristic analyses of the 3-level classification scheme will be compared

Countries

Belgium, France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 8, 2026